Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Abbott Laboratories : Trademark Application for "EARLY SHIELD" Filed by Abbott Laboratories

share with twitter share with LinkedIn share with facebook
share via e-mail
11/21/2017 | 09:04pm CET

By a News Reporter-Staff News Editor at Health & Medicine Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "EARLY SHIELD" by Elisa M. Valenzona, representing Abbott Laboratories. This application was made available to the public on November 10, 2017 (see also Trademarks).

The international trademark goods and services class code for this trademark application is 005.

The serial number for this application is 77930875.

The applicant indicates that "The color(s) gold, blue and white is/are claimed as a feature of the mark. The mark consists of a gold upside down triangular shaped shield encompassed within a smaller gold triangular shield with the word 'EarlyShield' in blue in the middle. The shield designs are in gold and separated by a white outline."

As submitted by the applicant, this trademark application relates to the following goods and services: Proprietary blend of ingredients, sold as an integral component of infant formula, namely, mix of immune supporting nucleotides, prebiotics and carotenoids, DHA (Omega-3) and ARA (Omega-6) carbohydrates, fats, antioxidants and vitamins and other dietary supplements designed to maximize baby health, immune system, brain and eyes and strong bones.

The owner/registrar information for this application is: Elisa M. Valenzona, Abbott Laboratories, 100 Abbott Park Rd, Abbott Park, IL 60064-6008.

Keywords for this news article include: Trademarks, Abbott Laboratories.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
11/21 ABBOTT LABORATORIES : Trademark Application for "EARLY SHIELD" Filed by Abbott L..
11/16 ABBOTT LABORATORIES : An Application for the Trademark "NURSE CURRENTS" Has Been..
11/16 ABBOTT LABORATORIES : An Application for the Trademark "THERAPEUTIC HYDRATION TO..
11/16 ABBOTT LABORATORIES : An Application for the Trademark "EAS PHOS FORCE" Has Been..
11/16 ABBOTT LABORATORIES : ' Trademark Application for "DIETETIC CURRENTS" Filed
11/15 HANGER,INC. (OTCMKTS : HNGR) Files An 8-K Departure of Directors or Certain Offi..
11/09 ABBOTT LABORATORIES : An Application for the Trademark "LIQUI-MIX SYSTEM" Has Be..
11/09 ABBOTT LABORATORIES : Mitraclip approved as first transcatheter mitral valve rep..
11/08 ABBOTT LABORATORIES : Federal Contracts Awarded by Federal Agencies in South Dak..
11/08 ABBOTT LABORATORIES : $28,890 Federal Contract Awarded to Abbott Laboratories
More news
News from SeekingAlpha
11/20 My 27 Stock Portfolio
11/19 Victory Formation Long/Short Portfolio Update - November 2017
11/17 Thursday Was About Wal-Mart And Cisco - Cramer's Mad Money (11/16/17)
11/17 Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q3 2017 Update
11/17 DIVIDEND CHALLENGERS (AND NEAR-CHALL : 58 Increases Expected By The End Of Janua..
Financials ($)
Sales 2017 27 185 M
EBIT 2017 6 008 M
Net income 2017 2 227 M
Debt 2017 19 729 M
Yield 2017 1,92%
P/E ratio 2017 47,29
P/E ratio 2018 35,28
EV / Sales 2017 4,30x
EV / Sales 2018 3,79x
Capitalization 97 126 M
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 61,6 $
Spread / Average Target 10%
EPS Revisions
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Executive VP-Finance
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON19.17%368 832
NOVARTIS12.82%222 846
ROCHE HOLDING LTD.6.15%216 979
PFIZER9.08%211 188
MERCK AND COMPANY-7.64%148 286